Clinical trials for professionals

The objective of this study is to evaluate XmAb24306 at different doses to determine whether it is safe in combination with cevostamab and how it is processed by the body. The study will also evaluate cevostamab in monotherapy.

We are conducting this trial to learn more about the drug Datopotomab-Deruxtecan (Dato-DXd) when used alone (monotherapy) and when used with other anticancer drugs (combination treatment).

The objective of this study is to see if JNJ-81201887 (also called AAVCAGsCD59) is safe and useful for treating patients with geographic atrophy secondary to age-related macular degeneration.

The aim of this study is to investigate whether the newly developed drug AP-325 can reduce neuropathic pain in patients suffering from ongoing neuralgia (neuropathic pain) after breast, thoracic, abdominal, varicose vein, gynecological or inguinal hernia repair surgery. In addition, how each patient tolerates AP-325 will be investigated and the AP-325 blood concentration will be measured.

The objective of this study is to determine the recommended dose of ibrutinib when administered together with rituximab and to test whether this combination is safe and effective in treating mantle cell lymphoma that has recurred ("relapsed") or was refractory to previous treatment ("refractory").

The aim of this study is to analyze the safety and tolerability of the study drug and to find out how it is processed by the body.

The objective of this study is to evaluate the efficacy and safety of the study drug (epcoritamab) when administered in combination with standard treatments, namely R-CHOP (rituximab, cyclophosphamide, oxorubicin, vincristine and prednisone) for newly diagnosed diffuse large B-cell lymphoma (DLBCL).

The goal of this research study is to find a safe dose of JNJ-75348780 that can be used to treat patients with B-lymphocyte non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Another goal is to find out how long JNJ-75348780 stays and acts in the body and how the body reacts to the drug.

The objective of the study is to demonstrate an improvement in the healing time of venous ulcers located in the lower extremities by the application of cold plasma at atmospheric air pressure, using the PlasmAction Med equipment.

Buntanetap has been shown to reduce the levels of several neurotoxic aggrecan proteins, which are key proteins involved in the progression of Parkinson's disease and other neurodegenerative disorders (a type of disease in which cells in the central nervous system [e.g., the brain] stop functioning). It is believed that buntanetap may improve the current treatment of Parkinson's disease. The goal of this research study is to test whether this study drug (buntanetap) is effective and safe ...